O	0	6	Impact	Impact	NN	B-NP
O	7	9	of	of	IN	B-PP
O	10	20	technology	technology	NN	B-NP
O	21	23	on	on	IN	B-PP
O	24	27	the	the	DT	B-NP
O	28	39	utilisation	utilisation	NN	I-NP
O	40	42	of	of	IN	B-PP
O	43	51	positron	positron	NN	B-NP
O	52	60	emission	emission	NN	I-NP
O	61	71	tomography	tomography	NN	I-NP
O	72	74	in	in	IN	B-PP
B-Cancer	75	83	lymphoma	lymphoma	NN	B-NP
O	83	84	:	:	:	O
O	85	92	current	current	JJ	B-NP
O	93	96	and	and	CC	I-NP
O	97	103	future	future	JJ	I-NP
O	104	116	perspectives	perspective	NNS	I-NP
O	116	117	.	.	.	O

O	118	126	Positron	Positron	NN	B-NP
O	127	135	emission	emission	NN	I-NP
O	136	146	tomography	tomography	NN	I-NP
O	147	148	(	(	(	O
O	148	151	PET	PET	NN	B-NP
O	151	152	)	)	)	O
O	153	156	has	have	VBZ	B-VP
O	157	160	now	now	RB	I-VP
O	161	167	gained	gain	VBN	I-VP
O	168	169	a	a	DT	B-NP
O	170	175	place	place	NN	I-NP
O	176	178	in	in	IN	B-PP
O	179	182	the	the	DT	B-NP
O	183	193	management	management	NN	I-NP
O	194	196	of	of	IN	B-PP
O	197	205	patients	patient	NNS	B-NP
O	206	210	with	with	IN	B-PP
B-Cancer	211	217	cancer	cancer	NN	B-NP
O	217	218	,	,	,	O
O	219	228	including	include	VBG	B-PP
O	229	234	those	those	DT	B-NP
O	235	239	with	with	IN	B-PP
O	240	247	Hodgkin	Hodgkin	NN	B-NP
O	247	248	'	'	POS	B-NP
O	248	249	s	s	NNS	I-NP
O	250	257	disease	disease	NN	I-NP
O	258	261	and	and	CC	O
B-Cancer	262	265	non	non	AFX	B-NP
I-Cancer	265	266	-	-	HYPH	I-NP
I-Cancer	266	273	Hodgkin	Hodgkin	NN	I-NP
I-Cancer	273	274	'	'	''	I-NP
I-Cancer	274	275	s	s	JJ	I-NP
I-Cancer	276	284	lymphoma	lymphoma	NN	I-NP
O	284	285	.	.	.	O

O	286	295	Restaging	Restaging	NN	B-NP
O	296	303	studies	study	NNS	I-NP
O	304	307	and	and	CC	O
O	308	313	those	those	DT	B-NP
O	314	324	addressing	address	VBG	B-VP
O	325	328	the	the	DT	B-NP
O	329	339	monitoring	monitoring	NN	I-NP
O	340	342	of	of	IN	B-PP
O	343	351	response	response	NN	B-NP
O	352	354	to	to	TO	B-PP
O	355	364	treatment	treatment	NN	B-NP
O	365	368	are	be	VBP	B-VP
O	369	379	especially	especially	RB	B-ADVP
O	380	382	in	in	IN	B-PP
O	383	388	focus	focus	NN	B-NP
O	388	389	.	.	.	O

O	390	394	Most	Most	JJS	B-NP
O	395	397	of	of	IN	B-PP
O	398	401	the	the	DT	B-NP
O	402	411	knowledge	knowledge	NN	I-NP
O	412	418	gained	gain	VBN	B-ADJP
O	419	422	has	have	VBZ	B-VP
O	423	427	been	be	VBN	I-VP
O	428	436	achieved	achieve	VBN	I-VP
O	437	441	with	with	IN	B-PP
O	442	451	dedicated	dedicate	VBN	B-NP
O	452	455	BGO	BGO	NN	I-NP
O	455	456	-	-	HYPH	B-VP
O	456	461	based	base	VBN	B-NP
O	462	465	PET	PET	NN	I-NP
O	466	476	technology	technology	NN	I-NP
O	476	477	,	,	,	O
O	478	481	but	but	CC	O
O	482	487	there	there	EX	B-NP
O	488	491	are	be	VBP	B-VP
O	492	493	a	a	DT	B-NP
O	494	500	number	number	NN	I-NP
O	501	503	of	of	IN	B-PP
O	504	516	developments	development	NNS	B-NP
O	517	521	that	that	WDT	B-NP
O	522	526	will	will	MD	B-VP
O	527	533	impact	impact	VB	I-VP
O	534	536	on	on	IN	B-PP
O	537	540	the	the	DT	B-NP
O	541	544	use	use	NN	I-NP
O	545	547	of	of	IN	B-PP
O	548	552	this	this	DT	B-NP
O	553	562	metabolic	metabolic	JJ	I-NP
O	563	570	imaging	imaging	NN	I-NP
O	571	580	technique	technique	NN	I-NP
O	581	583	in	in	IN	B-PP
O	584	587	the	the	DT	B-NP
O	588	601	investigation	investigation	NN	I-NP
O	602	604	of	of	IN	B-PP
O	605	613	patients	patient	NNS	B-NP
O	614	618	with	with	IN	B-PP
B-Cancer	619	627	lymphoma	lymphoma	NN	B-NP
O	627	628	.	.	.	O

O	629	632	The	The	DT	B-NP
O	633	643	challenges	challenge	NNS	I-NP
O	644	649	ahead	ahead	RB	B-ADVP
O	650	653	are	be	VBP	B-VP
O	654	664	determined	determine	VBN	I-VP
O	665	667	by	by	IN	B-PP
O	668	671	the	the	DT	B-NP
O	672	676	need	need	NN	I-NP
O	677	680	for	for	IN	B-PP
O	681	685	high	high	JJ	B-NP
O	685	686	-	-	HYPH	I-NP
O	686	693	quality	quality	NN	I-NP
O	694	699	whole	whole	JJ	I-NP
O	699	700	-	-	HYPH	I-NP
O	700	704	body	body	NN	I-NP
O	705	712	imaging	imaging	NN	I-NP
O	713	723	associated	associate	VBN	B-VP
O	724	728	with	with	IN	B-PP
O	729	738	increased	increase	VBN	B-NP
O	739	746	patient	patient	NN	I-NP
O	747	757	throughput	throughput	NN	I-NP
O	758	761	and	and	CC	O
O	762	765	the	the	DT	B-NP
O	766	770	need	need	NN	I-NP
O	771	773	to	to	TO	B-VP
O	774	785	investigate	investigate	VB	I-VP
O	786	789	the	the	DT	B-NP
O	790	794	role	role	NN	I-NP
O	795	797	of	of	IN	B-PP
O	798	801	new	new	JJ	B-NP
O	802	810	labelled	labelled	JJ	I-NP
O	811	818	ligands	ligand	NNS	I-NP
O	818	819	.	.	.	O

O	820	823	The	The	DT	B-NP
O	824	830	latter	latter	JJ	I-NP
O	831	834	are	be	VBP	B-VP
O	835	841	likely	likely	JJ	B-ADJP
O	842	844	to	to	TO	B-VP
O	845	850	yield	yield	VB	I-VP
O	851	854	new	new	JJ	B-NP
O	855	863	insights	insight	NNS	I-NP
O	864	868	into	into	IN	B-PP
B-Cell	869	875	tumour	tumour	NN	B-NP
I-Cell	876	880	cell	cell	NN	I-NP
O	881	897	characterisation	characterisation	NN	I-NP
O	897	898	,	,	,	O
B-Cancer	899	905	tumour	tumour	NN	B-NP
O	906	915	behaviour	behaviour	NN	I-NP
O	916	919	and	and	CC	O
B-Cancer	920	926	tumour	tumour	NN	B-NP
O	927	934	outcome	outcome	NN	I-NP
O	935	945	assessment	assessment	NN	I-NP
O	945	946	.	.	.	O

O	947	950	The	The	DT	B-NP
O	951	956	study	study	NN	I-NP
O	957	959	of	of	IN	B-PP
O	960	963	new	new	JJ	B-NP
O	964	977	radiolabelled	radiolabelled	JJ	I-NP
O	978	985	ligands	ligand	NNS	I-NP
O	986	990	will	will	MD	B-VP
O	991	997	impose	impose	VB	I-VP
O	998	1005	further	further	JJ	B-NP
O	1006	1013	demands	demand	NNS	I-NP
O	1014	1017	for	for	IN	B-PP
O	1018	1023	rapid	rapid	JJ	B-NP
O	1024	1031	dynamic	dynamic	JJ	I-NP
O	1032	1036	data	datum	NNS	I-NP
O	1037	1048	acquisition	acquisition	NN	I-NP
O	1049	1052	and	and	CC	O
O	1053	1061	accurate	accurate	JJ	B-NP
O	1062	1068	tracer	tracer	NN	I-NP
O	1069	1083	quantification	quantification	NN	I-NP
O	1083	1084	.	.	.	O

O	1085	1092	Current	Current	JJ	B-NP
O	1093	1096	and	and	CC	I-NP
O	1097	1103	future	future	JJ	I-NP
O	1104	1116	developments	development	NNS	I-NP
O	1117	1119	in	in	IN	B-PP
O	1120	1123	PET	PET	NN	B-NP
O	1124	1134	technology	technology	NN	I-NP
O	1135	1140	range	range	NN	I-NP
O	1141	1145	from	from	IN	B-PP
O	1146	1149	the	the	DT	B-NP
O	1150	1153	use	use	NN	I-NP
O	1154	1156	of	of	IN	B-PP
O	1157	1160	new	new	JJ	B-NP
O	1161	1169	detector	detector	NN	I-NP
O	1170	1179	materials	material	NNS	I-NP
O	1180	1182	to	to	TO	B-PP
O	1183	1192	different	different	JJ	B-NP
O	1193	1201	detector	detector	NN	I-NP
O	1202	1212	geometries	geometry	NNS	I-NP
O	1213	1216	and	and	CC	I-NP
O	1217	1221	data	datum	NNS	I-NP
O	1222	1233	acquisition	acquisition	NN	I-NP
O	1234	1239	modes	mode	NNS	I-NP
O	1239	1240	.	.	.	O

O	1241	1244	The	The	DT	B-NP
O	1245	1251	search	search	NN	I-NP
O	1252	1255	for	for	IN	B-PP
O	1256	1268	alternatives	alternative	NNS	B-NP
O	1269	1271	to	to	TO	B-PP
O	1272	1275	BGO	BGO	NN	B-NP
O	1276	1289	scintillation	scintillation	NN	I-NP
O	1290	1299	materials	material	NNS	I-NP
O	1300	1303	for	for	IN	B-PP
O	1304	1307	PET	PET	NN	B-NP
O	1308	1311	has	have	VBZ	B-VP
O	1312	1315	led	lead	VBN	I-VP
O	1316	1318	to	to	TO	B-PP
O	1319	1322	the	the	DT	B-NP
O	1323	1334	development	development	NN	I-NP
O	1335	1337	of	of	IN	B-PP
O	1338	1341	PET	PET	NN	B-NP
O	1342	1353	instruments	instrument	NNS	I-NP
O	1354	1363	utilising	utilise	VBG	B-VP
O	1364	1367	new	new	JJ	B-NP
O	1368	1376	crystals	crystal	NNS	I-NP
O	1377	1381	such	such	JJ	B-PP
O	1382	1384	as	as	IN	I-PP
O	1385	1388	LSO	LSO	NN	B-NP
O	1389	1392	and	and	CC	I-NP
O	1393	1396	GSO	GSO	NN	I-NP
O	1396	1397	.	.	.	O

O	1398	1401	The	The	DT	B-NP
O	1402	1405	use	use	NN	I-NP
O	1406	1408	of	of	IN	B-PP
O	1409	1414	these	these	DT	B-NP
O	1415	1418	new	new	JJ	I-NP
O	1419	1428	detectors	detector	NNS	I-NP
O	1429	1432	and	and	CC	O
O	1433	1436	the	the	DT	B-NP
O	1437	1446	increased	increase	VBN	I-NP
O	1447	1458	sensitivity	sensitivity	NN	I-NP
O	1459	1467	achieved	achieve	VBN	B-VP
O	1468	1472	with	with	IN	B-PP
O	1473	1475	3D	3D	NN	B-NP
O	1476	1480	data	datum	NNS	I-NP
O	1481	1493	acquisitions	acquisition	NNS	I-NP
O	1494	1503	represent	represent	VBP	B-VP
O	1504	1507	the	the	DT	B-NP
O	1508	1512	most	most	RBS	I-NP
O	1513	1524	significant	significant	JJ	I-NP
O	1525	1532	current	current	JJ	I-NP
O	1533	1545	developments	development	NNS	I-NP
O	1546	1548	in	in	IN	B-PP
O	1549	1552	the	the	DT	B-NP
O	1553	1558	field	field	NN	I-NP
O	1558	1559	.	.	.	O

O	1560	1564	With	With	IN	B-PP
O	1565	1568	the	the	DT	B-NP
O	1569	1579	increasing	increase	VBG	I-NP
O	1580	1587	demands	demand	NNS	I-NP
O	1588	1595	imposed	impose	VBN	B-VP
O	1596	1598	on	on	IN	B-PP
O	1599	1602	the	the	DT	B-NP
O	1603	1611	clinical	clinical	JJ	I-NP
O	1612	1623	utilisation	utilisation	NN	I-NP
O	1624	1626	of	of	IN	B-PP
O	1627	1630	PET	PET	NN	B-NP
O	1630	1631	,	,	,	O
O	1632	1638	issues	issue	NNS	B-NP
O	1639	1643	such	such	JJ	B-PP
O	1644	1646	as	as	IN	I-PP
O	1647	1652	study	study	NN	B-NP
O	1653	1657	cost	cost	NN	I-NP
O	1658	1661	and	and	CC	O
O	1662	1669	patient	patient	NN	B-NP
O	1670	1680	throughput	throughput	NN	I-NP
O	1681	1685	will	will	MD	B-VP
O	1686	1692	emerge	emerge	VB	I-VP
O	1693	1695	as	as	IN	B-PP
O	1696	1707	significant	significant	JJ	B-NP
O	1708	1714	future	future	JJ	I-NP
O	1715	1722	factors	factor	NNS	I-NP
O	1722	1723	.	.	.	O

O	1724	1726	As	As	IN	B-PP
O	1727	1728	a	a	DT	B-NP
O	1729	1740	consequence	consequence	NN	I-NP
O	1740	1741	,	,	,	O
O	1742	1745	low	low	JJ	B-NP
O	1745	1746	-	-	HYPH	I-NP
O	1746	1750	cost	cost	NN	I-NP
O	1751	1756	units	unit	NNS	I-NP
O	1757	1760	are	be	VBP	B-VP
O	1761	1766	being	be	VBG	I-VP
O	1767	1774	offered	offer	VBN	I-VP
O	1775	1777	by	by	IN	B-PP
O	1778	1781	the	the	DT	B-NP
O	1782	1795	manufacturers	manufacturer	NNS	I-NP
O	1796	1803	through	through	IN	B-PP
O	1804	1807	the	the	DT	B-NP
O	1808	1819	utilisation	utilisation	NN	I-NP
O	1820	1822	of	of	IN	B-PP
O	1823	1828	gamma	gamma	SYM	B-NP
O	1829	1835	camera	camera	NN	I-NP
O	1835	1836	-	-	HYPH	O
O	1836	1841	based	base	VBN	B-NP
O	1842	1846	SPET	SPET	NN	I-NP
O	1847	1854	systems	system	NNS	I-NP
O	1855	1858	for	for	IN	B-PP
O	1859	1862	PET	PET	NN	B-NP
O	1863	1874	coincidence	coincidence	NN	I-NP
O	1875	1882	imaging	imaging	NN	I-NP
O	1882	1883	.	.	.	O

O	1884	1897	Unfortunately	Unfortunately	RB	B-ADVP
O	1897	1898	,	,	,	O
O	1899	1907	clinical	clinical	JJ	B-NP
O	1908	1915	studies	study	NNS	I-NP
O	1916	1918	in	in	IN	B-PP
B-Cancer	1919	1927	lymphoma	lymphoma	NN	B-NP
O	1928	1931	and	and	CC	O
O	1932	1937	other	other	JJ	B-NP
B-Cancer	1938	1945	cancers	cancer	NNS	I-NP
O	1946	1950	have	have	VBP	B-VP
O	1951	1958	already	already	RB	I-VP
O	1959	1971	demonstrated	demonstrate	VBN	I-VP
O	1972	1975	the	the	DT	B-NP
O	1976	1987	limitations	limitation	NNS	I-NP
O	1988	1990	of	of	IN	B-PP
O	1991	1995	this	this	DT	B-NP
O	1996	2006	technology	technology	NN	I-NP
O	2006	2007	,	,	,	O
O	2008	2012	with	with	IN	B-PP
O	2013	2015	20	20	CD	B-NP
O	2015	2016	%	%	NN	I-NP
O	2017	2019	of	of	IN	B-PP
B-Cancer	2020	2027	lesions	lesion	NNS	B-NP
O	2028	2029	<	<	SYM	O
O	2029	2031	15	15	CD	B-NP
O	2032	2034	mm	mm	NN	I-NP
O	2035	2037	in	in	IN	B-PP
O	2038	2042	size	size	NN	B-NP
O	2043	2051	escaping	escape	VBG	B-VP
O	2052	2061	detection	detection	NN	B-NP
O	2061	2062	.	.	.	O

O	2063	2065	On	On	IN	B-PP
O	2066	2069	the	the	DT	B-NP
O	2070	2075	other	other	JJ	I-NP
O	2076	2080	hand	hand	NN	I-NP
O	2080	2081	,	,	,	O
O	2082	2085	the	the	DT	B-NP
O	2086	2092	recent	recent	JJ	I-NP
O	2093	2104	development	development	NN	I-NP
O	2105	2107	of	of	IN	B-PP
O	2108	2116	combined	combine	VBN	B-NP
O	2117	2120	PET	PET	NN	I-NP
O	2120	2121	/	/	SYM	B-NP
O	2121	2123	CT	CT	NN	B-NP
O	2124	2131	devices	device	NNS	I-NP
O	2132	2140	attempts	attempt	VBZ	B-VP
O	2141	2143	to	to	TO	I-VP
O	2144	2151	address	address	VB	I-VP
O	2152	2155	the	the	DT	B-NP
O	2156	2160	lack	lack	NN	I-NP
O	2161	2163	of	of	IN	B-PP
O	2164	2174	anatomical	anatomical	JJ	B-NP
O	2175	2186	information	information	NN	I-NP
O	2187	2195	inherent	inherent	JJ	B-ADJP
O	2196	2200	with	with	IN	B-PP
O	2201	2204	PET	PET	NN	B-NP
O	2205	2211	images	image	NNS	I-NP
O	2211	2212	,	,	,	O
O	2213	2219	taking	take	VBG	B-VP
O	2220	2229	advantage	advantage	NN	B-NP
O	2230	2232	of	of	IN	B-PP
O	2233	2240	further	further	JJ	B-NP
O	2241	2252	improvement	improvement	NN	I-NP
O	2253	2255	in	in	IN	B-PP
O	2256	2263	patient	patient	NN	B-NP
O	2264	2274	throughput	throughput	NN	I-NP
O	2275	2278	and	and	CC	O
O	2279	2284	hence	hence	RB	B-ADVP
O	2285	2289	cost	cost	AFX	B-NP
O	2289	2290	-	-	HYPH	I-NP
O	2290	2303	effectiveness	effectiveness	NN	B-NP
O	2303	2304	.	.	.	O

O	2305	2316	Preliminary	Preliminary	JJ	B-NP
O	2317	2324	studies	study	NNS	I-NP
O	2325	2330	using	use	VBG	B-VP
O	2331	2335	this	this	DT	B-NP
O	2336	2349	multimodality	multimodality	JJ	I-NP
O	2350	2357	imaging	imaging	NN	I-NP
O	2358	2366	approach	approach	NN	I-NP
O	2367	2371	have	have	VBP	B-VP
O	2372	2379	already	already	RB	I-VP
O	2380	2392	demonstrated	demonstrate	VBN	I-VP
O	2393	2396	the	the	DT	B-NP
O	2397	2406	potential	potential	NN	I-NP
O	2407	2409	of	of	IN	B-PP
O	2410	2413	the	the	DT	B-NP
O	2414	2423	technique	technique	NN	I-NP
O	2423	2424	.	.	.	O

O	2425	2433	Although	Although	IN	B-SBAR
O	2434	2437	the	the	DT	B-NP
O	2438	2447	potential	potential	NN	I-NP
O	2448	2454	exists	exist	VBZ	B-VP
O	2454	2455	,	,	,	O
O	2456	2463	certain	certain	JJ	B-NP
O	2464	2473	technical	technical	JJ	I-NP
O	2474	2480	issues	issue	NNS	I-NP
O	2481	2485	with	with	IN	B-PP
O	2486	2489	PET	PET	NN	B-NP
O	2489	2490	/	/	SYM	B-NP
O	2490	2492	CT	CT	NN	I-NP
O	2493	2500	require	require	VBP	B-VP
O	2501	2511	refinement	refinement	NN	B-NP
O	2512	2514	of	of	IN	B-PP
O	2515	2518	the	the	DT	B-NP
O	2519	2530	methodology	methodology	NN	I-NP
O	2530	2531	.	.	.	O

O	2532	2536	Such	Such	JJ	B-NP
O	2537	2543	issues	issue	NNS	I-NP
O	2544	2551	include	include	VBP	B-VP
B-Organ	2552	2557	organ	organ	NN	B-NP
O	2558	2566	movement	movement	NN	I-NP
O	2567	2568	(	(	(	O
O	2568	2572	such	such	JJ	B-PP
O	2573	2575	as	as	IN	I-PP
B-Anatomical_system	2576	2587	respiratory	respiratory	JJ	B-NP
O	2588	2594	motion	motion	NN	I-NP
O	2594	2595	)	)	)	O
O	2595	2596	,	,	,	O
O	2597	2602	which	which	WDT	B-NP
O	2603	2611	strongly	strongly	RB	B-VP
O	2612	2622	influences	influence	VBZ	I-VP
O	2623	2626	the	the	DT	B-NP
O	2627	2632	image	image	NN	I-NP
O	2633	2639	fusion	fusion	NN	I-NP
O	2640	2642	of	of	IN	B-PP
O	2643	2644	a	a	DT	B-NP
O	2645	2652	rapidly	rapidly	RB	I-NP
O	2653	2661	acquired	acquire	VBN	I-NP
O	2662	2664	CT	CT	NN	I-NP
O	2665	2669	scan	scan	NN	I-NP
O	2670	2674	with	with	IN	B-PP
O	2675	2678	the	the	DT	B-NP
O	2679	2685	slower	slow	JJR	I-NP
O	2686	2697	acquisition	acquisition	NN	I-NP
O	2698	2700	of	of	IN	B-PP
O	2701	2702	a	a	DT	B-NP
O	2703	2706	PET	PET	NN	I-NP
O	2707	2714	dataset	dataset	NN	I-NP
O	2714	2715	,	,	,	O
O	2716	2719	and	and	CC	O
O	2720	2723	the	the	DT	B-NP
O	2724	2734	derivation	derivation	NN	I-NP
O	2735	2737	of	of	IN	B-PP
O	2738	2740	CT	CT	NN	B-NP
O	2740	2741	-	-	HYPH	O
O	2741	2746	based	base	VBN	B-NP
O	2747	2758	attenuation	attenuation	NN	I-NP
O	2759	2771	coefficients	coefficient	NNS	I-NP
O	2772	2774	in	in	IN	B-PP
O	2775	2778	the	the	DT	I-PP
O	2779	2787	presence	presence	NN	I-PP
O	2788	2790	of	of	IN	I-PP
O	2791	2799	contrast	contrast	NN	B-NP
O	2800	2806	agents	agent	NNS	I-NP
O	2807	2809	or	or	CC	O
O	2810	2818	metallic	metallic	JJ	B-NP
O	2819	2827	implants	implant	NNS	I-NP
O	2827	2828	.	.	.	O

O	2829	2832	The	The	DT	B-NP
O	2833	2844	application	application	NN	I-NP
O	2845	2847	of	of	IN	B-PP
O	2848	2851	the	the	DT	B-NP
O	2852	2862	technology	technology	NN	I-NP
O	2863	2866	for	for	IN	B-PP
O	2867	2879	radiotherapy	radiotherapy	NN	B-NP
O	2880	2888	planning	planning	NN	I-NP
O	2889	2893	also	also	RB	B-ADVP
O	2894	2899	poses	pose	VBZ	B-VP
O	2900	2901	a	a	DT	B-NP
O	2902	2908	number	number	NN	I-NP
O	2909	2911	of	of	IN	B-PP
O	2912	2922	associated	associate	VBN	B-NP
O	2923	2933	challenges	challenge	NNS	I-NP
O	2933	2934	.	.	.	O

O	2935	2942	Finally	Finally	RB	B-ADVP
O	2942	2943	,	,	,	O
O	2944	2947	the	the	DT	B-NP
O	2948	2959	development	development	NN	I-NP
O	2960	2962	of	of	IN	B-PP
O	2963	2972	dedicated	dedicate	VBN	B-NP
O	2973	2976	PET	PET	NN	I-NP
O	2977	2984	systems	system	NNS	I-NP
O	2985	2990	based	base	VBN	B-PP
O	2991	2993	on	on	IN	B-PP
O	2994	3000	planar	planar	JJ	B-NP
O	3001	3009	detector	detector	NN	I-NP
O	3010	3022	arrangements	arrangement	NNS	I-NP
O	3023	3027	with	with	IN	B-PP
O	3028	3031	new	new	JJ	B-NP
O	3032	3040	detector	detector	NN	I-NP
O	3041	3051	components	component	NNS	I-NP
O	3052	3055	has	have	VBZ	B-VP
O	3056	3059	the	the	DT	B-NP
O	3060	3069	potential	potential	NN	I-NP
O	3070	3072	to	to	TO	B-VP
O	3073	3080	improve	improve	VB	I-VP
O	3081	3089	clinical	clinical	JJ	B-NP
O	3090	3100	throughput	throughput	NN	I-NP
O	3101	3103	by	by	IN	B-PP
O	3104	3108	over	over	IN	B-NP
O	3109	3112	100	100	CD	I-NP
O	3112	3113	%	%	NN	I-NP
O	3113	3114	,	,	,	O
O	3115	3118	but	but	CC	O
O	3119	3127	clinical	clinical	JJ	B-NP
O	3128	3134	trials	trial	NNS	I-NP
O	3135	3140	using	use	VBG	B-VP
O	3141	3145	such	such	JJ	B-NP
O	3146	3153	systems	system	NNS	I-NP
O	3154	3158	have	have	VBP	B-VP
O	3159	3164	still	still	RB	I-VP
O	3165	3167	to	to	TO	I-VP
O	3168	3170	be	be	VB	I-VP
O	3171	3178	carried	carry	VBN	I-VP
O	3179	3182	out	out	RP	B-PRT
O	3183	3185	in	in	IN	B-SBAR
O	3186	3191	order	order	NN	O
O	3192	3194	to	to	TO	B-VP
O	3195	3204	establish	establish	VB	I-VP
O	3205	3208	the	the	DT	B-NP
O	3209	3219	associated	associate	VBN	I-NP
O	3220	3225	whole	whole	JJ	I-NP
O	3225	3226	-	-	HYPH	I-NP
B-Organism_subdivision	3226	3230	body	body	NN	I-NP
O	3231	3236	image	image	NN	I-NP
O	3237	3244	quality	quality	NN	I-NP
O	3244	3245	.	.	.	O

